Advertisement

TOR

Target of Rapamycin

  • George Thomas
  • David M. Sabatini
  • Michael N. Hall

Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 279)

Table of contents

  1. Front Matter
    Pages I-X
  2. A. Lorberg, M. N. Hall
    Pages 1-18
  3. K. Düvel, J. R. Broach
    Pages 19-38
  4. T. Powers, I. Dilova, C.-Y. Chen, K. Wedaman
    Pages 39-51
  5. Y. Kamada, T. Sekito, Y. Ohsumi
    Pages 73-84
  6. B. Menand, C. Meyer, C. Robaglia
    Pages 97-113
  7. X. Long, F. Müller, J. Avruch
    Pages 115-138
  8. A.-C. Gingras, B. Raught, N. Sonenberg
    Pages 169-197
  9. J. C. Lawrence, T.-A. Lin, L. P. McMahon, K. M. Choi
    Pages 199-213
  10. D. H. Kim, D. M. Sabatini
    Pages 259-270
  11. K. Yonezawa, K.-I. Yoshino, C. Tokunaga, K. Hara
    Pages 271-282
  12. A. Jaeschke, P. B. Dennis, G. Thomas
    Pages 283-298
  13. M. Aoki, P. K. Vogt
    Pages 321-338
  14. P. J. Houghton, S. Huang
    Pages 339-359
  15. Back Matter
    Pages 361-366

About this book

Introduction

 

TOR, the Target of Rapamycin was discovered a little over ten years ago in a genetic screen in S. cerevisiae in search of mutants resistant to the cytostatic effects of the anti-mycotic, rapamycin. Since that time orthologues have been identified in all eukaryotes examined to date, including humans. Recent studies have placed TOR at the interface between nutrient sensing and the regulation of major anabolic and catabolic responses. The significance of understanding the molecular mechanisms which control TOR function has been underscored by Phase 1 clinical trials, showing that rapamycin is not only therapeutically important as an immunosuppressive but is also efficacious in the treatment of solid tumors. Indeed, currently, homologues of rapamycin are in broad-based trials to determine its use in the treatment of other pathological conditions, such as inflammation and restenosis. Given these observations a great deal of attention has been drawn to TOR and its role cellular homoeostasis and human disease. Here we have gathered the leading figures in the field to summarize their own contributions to uncovering TOR function and to speculate where they think the field will be moving in the next few years.

Keywords

Eukaryotes Phosphatases Protein Kinase Rapamycin Response Retroviral Oncogenes cell diseases eukaryota eukaryote fungi gene gene expression protein proteins yeast

Editors and affiliations

  • George Thomas
    • 1
  • David M. Sabatini
    • 2
  • Michael N. Hall
    • 3
  1. 1.Friedrich-Miescher-InstituteBaselSwitzerland
  2. 2.Whitehead InstituteCambridgeUSA
  3. 3.BiozentrumUniversity of BaselBaselSwitzerland

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-18930-2
  • Copyright Information Springer-Verlag Berlin Heidelberg 2004
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-62360-8
  • Online ISBN 978-3-642-18930-2
  • Series Print ISSN 0070-217X
  • Buy this book on publisher's site